Thursday 7th April 2016
|Text too small?|
Abano Healthcare, the listed medical and dental centre investor, expects an uplift in annual earnings as a strong performance from its New Zealand dental chain offsets a flat performance from its Australian dental business.
Underlying profit, which excludes one-time items, is expected to be between $8.2 million and $9 million in the year ending May 31, the Auckland-based company said in a statement. That compares with a year-earlier profit of $5.6 million in 2015 for its continuing businesses, or profit of $8.8 million including earnings from two businesses it has since sold, the company said.
Abano is investing to grow its chain of dental businesses in a fragmented market across Australia and New Zealand, where it aims to capture 10 percent of the $11 billion of revenue. So far this financial year it has acquired 13 dental practices, which are expected to add about $22 million in additional annualised gross revenue, and it has also opened one greenfield practice in Christchurch. As at March 31, the company had 186 practices generating annualised gross revenue of $250 million and said it has several more acquisitions planned before the end of the financial year.
Its Lumino The Dentists chain in New Zealand increased same-store sales 3 percent for the nine months ended Feb. 29 as it benefited from marketing, branding, improved margins and experienced management, the company said. Its Australian Maven Dental Group had a 4 percent decline in same-store revenue for the period as a weakening economy in Queensland state offset positive growth in its practices in New South Wales and Victoria, it said.
"The improving operating results are primarily being driven by a strong New Zealand dental performance offsetting a flat Australian dental performance; ongoing improvements from the audiology joint venture; and a stable performance from radiology," the company said. "We are moving towards a closer consolidation between our two dental businesses to share resources, knowledge and expertise."
Abano said its audiology joint venture in Australia is expected to "show a good uplift" from the year earlier with same-store sales growth of about 4 percent so far this financial year. Six new greenfield stores have been opened so far this financial year, adding incremental revenue and profit to the business with no additional support infrastructure cost, it said.
Its Ascot Radiology unit in Auckland is expected to deliver a stable performance in line with the year earlier as the company focuses on building demand for new technologies such as digital tomosynthesis mammography, while also expanding with the opening of a new CT scanning room and a new maternity scanning service.
The company sold its orthotics business in November 2014, reasoning the exposure to government contracts wasn't compatible with Abano's investment criteria to operate on a fee for service basis. It also divested its Aotea Pathology unit after quitting the lower North Island district health board tender process.
The company expects net profit of between $9.4 million and $10.2 million this financial year, compared with a year-earlier $4.5 million for its continuing businesses or a loss of $1.3 million including its divested businesses. It expects gross revenue, including audiology revenues and Australian dental revenues before payment of dentists' commissions, of $301 million to $305 million, compared with a year-earlier $265.8 million for its continuing businesses or $300.4 million including its divested businesses.
Abano's shares last traded at $7.05 and have slid 7 percent this year. The stock is rated an average 'hold' according to two analyst recommendations compiled by Reuters.
No comments yet
NZ dollar falls with Aussie after Westpac's RBA rate cut call
Intuit juggernaut grows QuickBooks subscribers but momentum slows
Reaction to Budget rules relaxation shows balance 'about right', says Ardern
Augusta lifts net profit six fold as investors flock into new funds
Annual exports to China top $15 billion for first time
Gentrack posts $8.7M loss on CA Plus write-down
Westpac says RBNZ capital proposals would add $6,000 p.a. to an Auckland mortgage
Cavalier says market conditions still challenging
Ryman hikes dividend as annual earnings grow on wider development margin
24th May 2019 Morning Report